Aerobic Exercise Training in Acute Ischaemic Stroke (ATAS)

August 16, 2023 updated by: Simon Nichols, Sheffield Hallam University

Aerobic Exercise Training in Acute Ischaemic Stroke: A Single-centre, Single-blinded, Randomised, Controlled Feasibility Study of an Aerobic Exercise Training Intervention Versus Standard Care Conducted in the Acute Phase of Stroke.

Stroke is a leading cause of adult disability in the UK. There are few treatment options that improve long-term disability outcomes after stroke. Animal studies indicate that aerobic exercise training can improve brain repair and reduce disability after stroke. However, in clinical practice it is difficult for stroke survivors to undertake aerobic exercise due to lower-limb disability and a lack of accessible exercise equipment. This study will assess the feasibility of implementing a 5-day aerobic exercise training intervention, beginning in the acute phase of stroke (1-7 days post-stroke), using a power-assisted exercise bike. Feasibility outcome measures: recruitment rate (30 participants recruited within 18 months), completeness of data (>80% of planned measurements recorded) and the safety (<10 adverse events related to the intervention) and acceptability (>3/5 comfort scale) of the intervention. We will also investigate the acute effects of aerobic exercise on cerebral blood flow velocity using transcranial Doppler ultrasound, and brain-derived neurotrophic factor (serum and plasma).

Study Overview

Detailed Description

Introduction

Pre-clinical studies indicate that aerobic exercise training can enhance brain repair and reduce disability when initiated early (1-7 days) after stroke. However, in the real-world clinical setting, most acute stroke patients have a lower-limb disability which makes it difficult to engage in aerobic exercise. Power-assisted exercise bikes can detect lower-limb motor deficits and compensate with motorised assistance. The primary aim of this study is to assess the feasibility of implementing a 5-day power-assisted aerobic exercise training programme, initiated in the acute phase of ischaemic stroke (1-7 days post-stroke). Key feasibility outcomes related to the intervention include safety (<10 adverse events related to the intervention) and acceptability (>3/5 comfort scale). The secondary aim is to assess the feasibility of conducting a randomised controlled trial (RCT), with a focus on study procedures including recruitment (30 participants recruited within 18 months) and completeness of data (≥80% of planned measurements recorded), and identification of a suitable primary outcome measure for a large-scale RCT.

Recruitment

People with acute ischaemic stroke admitted to the Royal Hallamshire Hospital (Sheffield, England) will be recruited to this study. After eligible individuals provide informed consent, a web-based permuted block randomisation procedure will be used to allocate participants into one of two study arms: 1) usual care; or 2) aerobic exercise training plus usual care. Participants will be stratified using the National Institutes of Health Stroke Scale (NIHSS): mild to moderate (0-15) and moderate to severe (>15) measured after reperfusion therapy or at a similar timepoint if not eligible for reperfusion therapy. Accounting for a predicted attrition rate of 20%, the target sample size is 30 participants.

Intervention

A bedside power-assisted exercise bike will be used to enable patients to undertake aerobic exercise whilst remaining in their bed, even if they have a lower-limb disability. The aerobic exercise programme will consist of five exercise sessions, each including a graduated warm-up, a conditioning phase, and a graduated cooldown. The conditioning phase will be an interval training format, with five-minute low- to moderate-intensity intervals interspersed with one-minute rest periods. The number of five-minute conditioning bouts will increase by one bout per session. The first session will contain two bouts (total = 10 mins), and the fifth session will contain six bouts (total = 30 mins). The rationale for this progressive design was developed with input from researchers, healthcare practitioners and people affected by stroke. Briefly, it was considered that starting with 30 minutes of aerobic exercise in the first session may be too difficult for some patients due to fatigue, whereas a gradual progression in exercise duration would be more tolerable. In addition, the interval training design was chosen to reduce exercise-induced fatigue, and thereby increase the total duration of aerobic exercise completed per session. Participants will cycle at a steady self-selected cadence, and exercise intensity will be guided by the Borg rating of perceived exertion (RPE) scale. During the conditioning intervals, participants will be asked to the cycle at an intensity equivalent to 'somewhat hard' (RPE:13/20). Heart rate, peripheral oxygen saturation, brachial blood pressure, and symptoms will be monitored throughout each exercise session. In the fourth or fifth exercise session, exercise-induced changes in respiratory gases, cerebral blood flow velocity and blood-borne brain-derived neurotrophic factor will be assessed. Established clinical exercise physiology guidelines will be followed with regards to exercise contraindications and termination criteria.

Usual care

Participants randomised to the control group will receive usual care according to guidance from the National Institute for Health and Care Excellence and the Royal College of Physicians. Briefly, it is recommended that patients undertake at least 45 minutes of each appropriate therapy per day (physiotherapy, occupational therapy and or speech and language therapy) for five days per week. Patients should be mobilised (out-of-bed sitting, standing or walking) within the first 48 hours of stroke onset, or if physically capable, as soon as possible post-stroke.

Interviews

7-14 days after enrolling in the study, a convenience sample of participants (n=8 per study arm) will be interviewed to gain insight into participants' experiences participating in the study activities (e.g. intervention and or assessments). Repeat interviews will be conducted with the same individuals three months later with a focus on their post-hospital rehabilitation experiences. In addition, a small convenience sample (n=3-5) of clinical staff members will be interviewed to understand their opinions about the intervention and overall study procedures.

Study Type

Interventional

Enrollment (Actual)

30

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • South Yorkshire
      • Sheffield, South Yorkshire, United Kingdom, S10 2JF
        • Royal Hallamshire Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Adult (age >18 years) patients diagnosed with acute ischaemic stroke 1-7 days previously.
  • Medically stable, assessed by a stroke physician.
  • Sufficient English language comprehension and cognitive ability to understand the study protocol, follow instructions, complete questionnaires and give informed consent.
  • Ability to mobilise lower body limbs in a cyclical manner (at least one leg).
  • Likely to be admitted to the Royal Hallamshire Hospital for at least 7 days.

Exclusion Criteria:

  • Haemorrhagic stroke.
  • <1 day or >7 days after onset of stroke symptoms.
  • Clinically unstable, assessed by stroke physician.
  • Disability preventing unipedal cycling.
  • New York Heart Failure Classification stage III/IV.
  • Terminal illness (life expectancy <6 months).
  • Resting blood pressure >180/110 mmHg.
  • Uncontrolled arrhythmia causing symptoms or haemodynamic compromise.
  • Unstable angina.
  • Uncontrolled diabetes mellitus.
  • Acute deep vein thrombosis, pulmonary embolism or pulmonary infection.
  • Already participating in a clinical research trial.
  • Pain during mobilisation of lower-limbs.
  • Lower-limb spasticity or contracture which impairs ability to cycle.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Other
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Intervention
5-day, power-assisted, low- to moderate-intensity, aerobic exercise training programme. Exercise duration to progress from 10 minutes on day 1, to 30 minutes on day 5. Exercise equipment: Letto-2 (Motomed, Germany).
No Intervention: Usual care

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Safety of aerobic exercise training
Time Frame: 21 months

The following traffic light-style system is proposed:

  • Red: >10 adverse events related to the intervention - do not proceed.
  • Amber: 5-10 adverse events related to the intervention - review and revise protocol.
  • Green: <5 adverse events related to the intervention - proceed.
21 months
Acceptability of aerobic exercise training
Time Frame: 18 months
Average comfort score > 3/5 Likert scale (1= very uncomfortable to 5= very comfortable)
18 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Feasibility of recruitment
Time Frame: 18 months
Recruitment rate: ≥2 participants per month (30 participants recruited in 18 months)
18 months
Feasibility of data collection
Time Frame: 21 months
Completeness of data: ≥80% of planned measurements recorded
21 months

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Rectus femoris cross sectional area
Time Frame: Baseline, 1 week and 3 months
Rectus femoris cross sectional area measured using ultrasound
Baseline, 1 week and 3 months
Rectus femoris muscle thickness
Time Frame: Baseline, 1 week and 3 months
Rectus femoris muscle thickness measured using ultrasound
Baseline, 1 week and 3 months
Vastus lateralis muscle thickness
Time Frame: Baseline, 1 week and 3 months
Vastus lateralis muscle thickness measured using ultrasound
Baseline, 1 week and 3 months
Vastus lateralis angle of pennation
Time Frame: Baseline, 1 week and 3 months
Vastus lateralis angle of pennation measured using ultrasound
Baseline, 1 week and 3 months
Cognitive function
Time Frame: Baseline, 3 months
Montreal Cognitive Assessment
Baseline, 3 months
Anxiety and depression
Time Frame: 1 week, 3 months
Hospital Anxiety and Depression Scale
1 week, 3 months
Optimism
Time Frame: Baseline, 3 months
Revised Life Orientation Test
Baseline, 3 months
Exercise self-efficacy
Time Frame: Baseline, 1 week and 3 months
Self-Efficacy for Exercise Scale
Baseline, 1 week and 3 months
Health-related quality of life
Time Frame: Baseline, 3 months
EuroQol 5-Dimensional
Baseline, 3 months
Inpatient physical activity levels
Time Frame: Worn for 1 week in hospital
Thigh-mounted accelerometer
Worn for 1 week in hospital
Post-discharge physical activity levels (short-term)
Time Frame: Worn for 2 weeks post-discharge
Wrist-worn accelerometer
Worn for 2 weeks post-discharge
Post-discharge physical activity levels (long-term)
Time Frame: 3 months
Global Physical Activity Questionnaire
3 months
Chronic fatigue
Time Frame: Baseline, 3 months
Chronic Fatigue Scale
Baseline, 3 months
Lower-extremity function
Time Frame: Baseline, 1 week and 3 months
Short physical performance battery (standing balance, sit-to-stand, 3-metre walk)
Baseline, 1 week and 3 months
Upper-extremity function
Time Frame: Baseline, 1 week and 3 months
Handgrip strength (dynamometer)
Baseline, 1 week and 3 months
Disability
Time Frame: Baseline and 3 months
Modified Rankin Scale
Baseline and 3 months
Functional independence
Time Frame: Baseline, 4-8 weeks, 3 months
Barthel Index
Baseline, 4-8 weeks, 3 months
Aerobic exercise-induced changes in cerebral blood flow velocity
Time Frame: Day 5 or 6 (measured for approximately 1 hour during exercise session)
Mean cerebral blood flow velocity, measured bilaterally at the middle cerebral arteries using transcranial Doppler ultrasound
Day 5 or 6 (measured for approximately 1 hour during exercise session)
Aerobic exercise-induced changes in mature brain-derived neurotrophic factor (BDNF)
Time Frame: Day 5 or 6 (pre-post exercise)
Blood collection at rest and within 5 minutes of ceasing aerobic exercise session. Serum and plasma BDNF will be measured using enzyme-linked immunosorbent assays
Day 5 or 6 (pre-post exercise)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Tom Maden-Wilkinson, PhD, Sheffield Hallam University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

April 27, 2021

Primary Completion (Actual)

August 25, 2022

Study Completion (Actual)

August 25, 2022

Study Registration Dates

First Submitted

January 19, 2021

First Submitted That Met QC Criteria

February 2, 2021

First Posted (Actual)

February 8, 2021

Study Record Updates

Last Update Posted (Actual)

August 21, 2023

Last Update Submitted That Met QC Criteria

August 16, 2023

Last Verified

August 1, 2023

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

We will have exclusive access to the data for 24 months after the end date of the study whilst we develop a protocol and grant application, and publish our findings.

Data will be accessible before 24 months should these objectives be achieved earlier than expected. Anonymised data will be provided on application rather than be offered open access. A description of the data will be placed on the University open access repository (SHURDA).

Data sharing will be subject to an application. No sensitive/personal data will be made available.

All external users of our data will be bound by a data sharing agreement between the research team, the University, and the user themselves. Data will be supplied on the condition that their research is non-profit, and that their findings will be published in an open access domain. Data users will not be permitted to share the data with anyone outside of their immediate research team.

IPD Sharing Time Frame

Study protocol publication: <12 months of trial initiation. Clinical study report: <24 months after trial end date.

IPD Sharing Access Criteria

Data sharing enquires may be sent to Dr Simon Nichols, s.j.nichols@shu.ac.uk.

IPD Sharing Supporting Information Type

  • STUDY_PROTOCOL
  • CSR

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Ischemic Stroke

Clinical Trials on Aerobic exercise training

Subscribe